Drug Profile
SYN 023
Alternative Names: CTB-011/CTB-012; CTB-012/CTB-011; SYN-023Latest Information Update: 02 Jan 2023
Price :
$50
*
At a glance
- Originator Synermore Biologics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Rabies
Most Recent Events
- 02 Jan 2023 SYN 023 is still in phase II and II/III trials for Rabies (Prevention) in USA and Philippines(NCT03961555)
- 16 Dec 2022 Synermore Biologics completes a Phase-III clinical trials in Rabies (Prevention) in China (IM) (NCT04644484)
- 23 Dec 2021 Synemore Biologics completes a phase II trial in Rabies (Prevention) in Philippines (IM,SC) (NCT03961555)